GXO Logistics Inc vs Novavax Inc — how do they compare? GXO Logistics Inc trades at $53.55 (market cap $6.02B), while Novavax Inc trades at $8.22 (market cap $1.39B). The key difference: GXO Logistics Inc is far larger — about 4.3× Novavax Inc's market cap. Which is the better fit depends on your goals.
| GXO | NVAX | |
|---|---|---|
Market Cap | $6.02B | $1.39B |
Sector | Industrials | Health |
52-Week High | $65.59 | $11.19 |
52-Week Low | $45.52 | $6.22 |
Enterprise Value | $11.18B | $890.94M |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics (GXO) trades at $53.69, up 8.09% in the last session, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, including Q1 2026, and reported Q1 2026 revenue growth of 10.8% year-over-year. Positive news includes new partnership renewals and an upcoming Investor Day, reinforcing its position as the world's largest pure-play contract logistics provider.
The outlook is positive, with a consensus price target of $66.60 implying significant upside. Investment opportunities stem from operational growth and strategic focus on high-margin sectors, but risks include competitive pressures from Amazon and reliance on the retail sector. Earnings on August 5, 2026, will be a key catalyst.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →